Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Besse

Showing results (111-120 of 512) with videos related to

Pageof 52
Sort By:
Clinical Lung Cancer|February 25, 2016
The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Benjamin Besse, Julie Renee Brahmer, et al.
Cancer Treatment Reviews|June 9, 2018
Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatmentElie El Rassy, Angela Botticella, Joseph Kattan, et al.
Cancer Treatment Reviews|April 26, 2022
The use of immunotherapy in older patients with advanced non-small cell lung cancerMarco Tagliamento, Maxime Frelaut, Capucine Baldini, et al.
Clinical Lung Cancer|September 8, 2020
Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAF<sup>V600E</sup>-Mutant Metastatic Non-Small-Cell Lung CancerNuria Chic, Laura Mezquita, Mihaela Aldea, et al.
Critical Reviews in Oncology/Hematology|August 2, 2022
Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: A systematic reviewDaniele Presti, Filippo Gustavo Dall'Olio, Benjamin Besse, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2014
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLCStéphane Champiat, Ecaterina Ileana, Giuseppe Giaccone, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 10, 2018
Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer PatientsArthur Geraud, Laura Mezquita, Frederic Bigot, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 23, 2014
Dendritic cell-derived exosomes as immunotherapies in the fight against cancerJonathan M Pitt, Mélinda Charrier, Sophie Viaud, et al.
Nature Reviews. Clinical Oncology|October 27, 2018
Hyperprogressive disease: recognizing a novel pattern to improve patient managementStéphane Champiat, Roberto Ferrara, Christophe Massard, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 15, 2019
Hepatic Intra-Arterial Chemotherapy With Immunotherapy in NSCLCJose Carlos Benitez, Laura Mezquita, Rapahël Colle, et al.
Pageof 52

Showing results (111-120 of 512) with videos related to

Sort By:
Pageof 52
Clinical Lung Cancer|February 25, 2016
The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic OncologyCesare Gridelli, Benjamin Besse, Julie Renee Brahmer, et al.
Cancer Treatment Reviews|June 9, 2018
Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatmentElie El Rassy, Angela Botticella, Joseph Kattan, et al.
Cancer Treatment Reviews|April 26, 2022
The use of immunotherapy in older patients with advanced non-small cell lung cancerMarco Tagliamento, Maxime Frelaut, Capucine Baldini, et al.
Clinical Lung Cancer|September 8, 2020
Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAF<sup>V600E</sup>-Mutant Metastatic Non-Small-Cell Lung CancerNuria Chic, Laura Mezquita, Mihaela Aldea, et al.
Critical Reviews in Oncology/Hematology|August 2, 2022
Tumor infiltrating lymphocytes (TILs) as a predictive biomarker of response to checkpoint blockers in solid tumors: A systematic reviewDaniele Presti, Filippo Gustavo Dall'Olio, Benjamin Besse, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2014
Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLCStéphane Champiat, Ecaterina Ileana, Giuseppe Giaccone, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 10, 2018
Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer PatientsArthur Geraud, Laura Mezquita, Frederic Bigot, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 23, 2014
Dendritic cell-derived exosomes as immunotherapies in the fight against cancerJonathan M Pitt, Mélinda Charrier, Sophie Viaud, et al.
Nature Reviews. Clinical Oncology|October 27, 2018
Hyperprogressive disease: recognizing a novel pattern to improve patient managementStéphane Champiat, Roberto Ferrara, Christophe Massard, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 15, 2019
Hepatic Intra-Arterial Chemotherapy With Immunotherapy in NSCLCJose Carlos Benitez, Laura Mezquita, Rapahël Colle, et al.
Pageof 52